SCHEDULE 13G: Suvretta Capital Management and Affiliates Disclose Significant Stake in Immatics N.V.

Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have jointly filed a Schedule 13G, revealing beneficial ownership of 6.5% of Immatics N.V.'s ordinary shares.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have jointly filed a Schedule 13G with the SEC.
• The filing discloses beneficial ownership of ordinary shares, nominal value €0.01 per share, of Immatics N.V. (CUSIP N44445109).
• Suvretta Capital Management, LLC and Aaron Cowen each beneficially own 7,881,608 shares, representing 6.5% of the class.
• Averill Master Fund, Ltd. beneficially owns 6,985,378 shares, representing 5.7% of the class.
• All reporting persons hold shared voting and shared dispositive power over their reported shares.
• The shares were acquired as of February 4, 2025.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Immatics N.V.

Sentiment

Score: 5

Explanation: The document is a factual regulatory disclosure of beneficial ownership, inherently neutral in sentiment regarding the issuer's performance or outlook.

Positives

• The disclosure of significant beneficial ownership by institutional investors like Suvretta Capital Management, LLC and Averill Master Fund, Ltd. (6.5% and 5.7% respectively) can be interpreted as a vote of confidence in Immatics N.V.'s prospects.
• The filing indicates a passive investment, as the reporting persons certify that the shares were not acquired for the purpose of changing or influencing control of the issuer.

Risks

• The reporting persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and the report is not an admission of beneficial ownership for Section 16 purposes of the Securities Exchange Act of 1934.
• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, which means no activist pressure is intended from these shareholders.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Immatics N.V.'s future performance or strategic direction.

Industry Context

This filing indicates a significant investment by a hedge fund and an associated master fund in a biotechnology company, Immatics N.V., which is common for institutional investors seeking exposure to the life sciences sector. It reflects a specific investment decision rather than broader industry trends.

Related Party Transactions

• All of the securities reported in this Schedule 13G are directly owned by advisory clients of Suvretta Capital Management, LLC.
• Averill Master Fund, Ltd. is an advisory client of Suvretta Capital Management, LLC and is deemed to beneficially own more than 5% of the ordinary shares.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding significant institutional ownership, which can influence investor perception and potentially stock liquidity.
• Management: Awareness of a significant passive institutional stake may influence future investor relations strategies.

Key Dates

Keywords

Immatics N.V., Schedule 13G, Beneficial Ownership, Suvretta Capital Management, Averill Master Fund, Aaron Cowen, Institutional Investment, SEC Filing, Ordinary Shares, Biotechnology, Pharmaceuticals